Understanding Raloxifex –
Raloxifene is a selective estrogen receptor modulator (SERM) belonging to the benzothiophene class of compounds. Originally developed by Eli Lilly, this second-generation SERM demonstrates tissue-selective activity at estrogen receptors, functioning as an agonist in bone tissue while acting as an antagonist in breast and uterine tissue. Researchers at Stroid UK Shop can examine this compound’s unique receptor selectivity profile in controlled laboratory environments. Each tablet contains 60mg of raloxifene hydrochloride in a pharmaceutical-grade formulation suitable for analytical studies.
Laboratory Applications
Research scientists investigate raloxifene’s dual mechanisms across different tissue types in experimental models. Studies examine its ability to bind estrogen receptor alpha and beta subtypes with varying affinities, demonstrating approximately 3-fold selectivity for ERα over ERβ. The compound’s bioavailability characteristics and hepatic metabolism pathways make it valuable for pharmacokinetic research. Investigators studying aromatase inhibitors and SERMs often compare raloxifene’s tissue-selective properties against other estrogen receptor modulators. Research applications extend to bone metabolism studies, where scientists analyse its effects on osteoblast and osteoclast activity in cellular assays. Additionally, researchers examining hormonal signalling pathways utilise raloxifene to study estrogen receptor-mediated gene expression in various cell lines. Scientists working with selective androgen receptor modulators may investigate cross-talk between estrogen and androgen signalling systems. Comparative studies with peptide hormones help elucidate complex endocrine interactions in research models.
Compound Specifications
| Parameter | Value |
|---|---|
| Chemical Name | 6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl [4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone hydrochloride |
| CAS Number | 82640-04-8 |
| Molecular Formula | C₂₈H₂₇NO₄S·HCl |
| Molecular Weight | 510.04 g/mol |
| Dosage Form | 60mg tablets |
| Package Size | 40 tablets per blister |
| Manufacturer | Euro-Pharmacies |
| Storage | Room temperature, dry conditions |
Research Compliance
This raloxifene hydrochloride formulation is manufactured exclusively for in-vitro research purposes and analytical laboratory studies. Not approved for human consumption, therapeutic use, or clinical applications. Researchers must maintain appropriate laboratory safety protocols and documentation when handling this research chemical. All studies should comply with institutional guidelines for chemical research and proper waste disposal procedures.
